Page last updated: 2024-12-07

des-enkephalin-gamma-endorphin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID123641
MeSH IDM0104057

Synonyms (9)

Synonym
74174-40-6
degammae
des-enkephalin-gamma-endorphin
org 5878
alpha-endorphin, 1-de-l-tyrosine-2-deglycine-3-deglycine-4-de-l-phenylalanine-5-de-l-methionine-16a-l-leucine-
beta-lph(66-77)
beta-lipotropin 66-77
beta-endorphin(6-17)
org-5878

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The stability of the neuroleptic peptide des-enkephalin-gamma-endorphin (DE gamma E; Org 5878) in the rectal lumen and the rectal bioavailability of DE gamma E were investigated in conscious rats."( Rectal absorption enhancement of des-enkephalin-gamma-endorphin (DE gamma E) by medium-chain glycerides and EDTA in conscious rats.
Breimer, DD; de Boer, AG; Heijligers-Feijen, CD; van Hoogdalem, EJ; Verhoef, JC, 1989
)
0.82
" The bioavailability of DE gamma E for this route of administration was shown to be 20-23%."( Des-enkephalin-gamma-endorphin (DE gamma E): pharmacokinetics in dogs after intravenous and subcutaneous administration.
van den Wildenberg, HM; Verhoef, J,
)
1.57
" Hence, improvement of the transdermal bioavailability of the peptide will most likely be obtained chiefly by enhancing its flux (possibly through iontophoresis), intra(epi-)dermal degradation being a problem of only minor importance."( Transdermal peptide delivery.
Bodde, HE; Ponec, M; Verhoef, JC, 1989
)
0.28
" The absolute bioavailability of DE gamma E after subcutaneous injection amounted to 30."( Des-enkephalin-gamma-endorphin: bioavailability in rats following the subcutaneous and intramuscular route of administration.
van den Wildenberg, HM; Verhoef, JC, 1986
)
1.71

Dosage Studied

ExcerptRelevanceReference
" gamma E (beta-LPH-(61-77)), beta-endorphin-(1-17)), and DT gamma E (beta-LPH-(62-77), beta-endorphin-(2-17)) were without effect in the dosage used."( The effect of gamma-type endorphins on alpha-MSH release in the rat.
Andringa-Bakker, EA; de Rotte, AA; de Wied, D; van de Buuse, M; van Wimersma Greidanus, TB, 1985
)
0.27
"After intravenous dosing in dogs [3H-Lys9]-DE gamma E (Org 5878) was very rapidly eliminated from the circulation."( Des-enkephalin-gamma-endorphin (DE gamma E): pharmacokinetics in dogs after intravenous and subcutaneous administration.
van den Wildenberg, HM; Verhoef, J,
)
1.57
" In some cases, effective transdermal dosing has been achieved in vivo, especially with the aid of iontophoresis."( Transdermal peptide delivery.
Bodde, HE; Ponec, M; Verhoef, JC, 1989
)
0.28
" These are characterized by the slope of the dose-response curve for the substances to antagonize the apomorphine-induced behavioral effects and by the effectiveness of DE gamma E in this respect."( Antipsychotic substances and dopamine in the rat brain; behavioral studies reveal distinct dopamine receptor systems.
Elands, J; Király, I; Van Ree, JM; Wolterink, G, 1989
)
0.28
" The response to DE gamma E appeared to be negatively correlated with the dosage of neuroleptic medication and the duration of the last psychotic episode."( Antipsychotic properties of Des-enkephalin-gamma-endorphin in treatment of schizophrenic patients.
de Wied, D; Heezius-van Bentum, A; van Praag, HM; van Ree, JM; Verhoeven, WM, 1982
)
0.56
" The gamma-type endorphin exhibited an inverted U-shaped dose-response curve on passive avoidance behavior but not on extinction of pole-jumping avoidance behavior."( Effect of des-Tyr1-gamma-endorphin and des-enkephalin-gamma-endorphin on active and passive avoidance behavior of rats; a dose-response relationship study.
De Wied, D; Gaffori, O, 1982
)
0.53
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (36)

TimeframeStudies, This Drug (%)All Drugs %
pre-199024 (66.67)18.7374
1990's9 (25.00)18.2507
2000's3 (8.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.17

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.17 (24.57)
Research Supply Index3.87 (2.92)
Research Growth Index4.04 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.17)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (14.63%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (2.44%)4.05%
Observational0 (0.00%)0.25%
Other34 (82.93%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]